Laboratory Company Top Insiders
LH Stock | USD 243.04 0.68 0.28% |
Under 71% of Laboratory's corporate insiders are selling. The analysis of insiders' sentiment of trading Laboratory of stock suggests that many insiders are alarmed at this time. Laboratory employs about 60.9 K people. The company is managed by 36 executives with a total tenure of roughly 175 years, averaging almost 4.0 years of service per executive, having 1691.67 employees per reported executive.
Adam Schechter Chairman Chairman of the Board, President, Chief Executive Officer |
Glenn Eisenberg President Chief Financial Officer, Executive Vice President |
Insider Sentiment 29
Mostly Selling
Selling | Buying |
Latest Trades
2025-07-01 | Kerrii B Anderson | Disposed 500 @ 265 | View | ||
2025-06-27 | Ro Khanna | Disposed @ 260.3 | |||
2025-06-23 | Ro Khanna | Disposed @ 261.01 | |||
2025-06-11 | Kerrii B Anderson | Disposed 500 @ 260 | View | ||
2025-06-03 | Brian J Caveney | Disposed 2000 @ 247 | View | ||
2025-05-28 | Ro Khanna | Acquired @ 246.89 | |||
2025-05-15 | Robert Bresnahan, Jr. | Acquired @ 246.18 | |||
2025-05-12 | Adam H Schechter | Disposed 6105 @ 248.73 | View | ||
2025-05-01 | Peter J Wilkinson | Disposed 829 @ 242.26 | View | ||
2025-04-08 | Robert Bresnahan, Jr. | Disposed @ 217.34 | |||
2025-03-31 | Gilbert Ray Cisneros, Jr. | Disposed @ 232.8 | |||
2025-03-28 | Amy B Summy | Disposed 758 @ 231.67 | View | ||
2025-03-05 | Kerrii B Anderson | Disposed 500 @ 255.63 | View | ||
2025-02-28 | April McClain Delaney | Acquired @ 251.45 | |||
2025-02-27 | April McClain Delaney | Acquired @ 247.89 | |||
2025-02-25 | Robert Bresnahan, Jr. | Acquired @ 253.07 | |||
2025-02-24 | Amy B Summy | Disposed 226 @ 250.4 | View |
Monitoring Laboratory's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Acquired vs Disposed
Filed vs Not Filed
Insider sentiment refers to the collective sentiment or feeling of Laboratory's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Laboratory of. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Laboratory's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
Laboratory | Build AI portfolio with Laboratory Stock |
Laboratory's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Laboratory's future performance. Based on our forecasts, it is anticipated that Laboratory will maintain a workforce of under 60900 employees by August 2025.Laboratory's latest congressional trading
Congressional trading in companies like Laboratory, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Laboratory by those in governmental positions are based on the same information available to the general public.
2025-07-10 | Representative Ro Khanna | Acquired Under $15K | Verify | ||
2025-05-08 | Representative Rob Bresnahan | Acquired Under $15K | Verify | ||
2025-04-08 | Representative Gilbert Cisneros | Acquired Under $15K | Verify | ||
2025-03-28 | Representative Rob Bresnahan | Acquired Under $15K | Verify | ||
2025-03-21 | Representative John Delaney | Acquired Under $15K | Verify | ||
2023-09-22 | Senator Dan Sullivan | Acquired Under $15K | Verify | ||
2023-09-17 | Senator Dan Sullivan | Acquired Under $15K | Verify | ||
2020-08-12 | Senator James Inhofe | Acquired $50K to $100K | Verify | ||
2019-05-03 | Senator James Inhofe | Acquired $50K to $100K | Verify |
Laboratory Management Team Effectiveness
The company has Return on Asset (ROA) of 0.0418 % which means that for every $100 of assets, it generated a profit of $0.0418. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.0898 %, which means that it produced $0.0898 on every 100 dollars invested by current stockholders. Laboratory's management efficiency ratios could be used to measure how well Laboratory manages its routine affairs as well as how well it operates its assets and liabilities. As of now, Laboratory's Return On Tangible Assets are decreasing as compared to previous years. The Laboratory's current Return On Equity is estimated to increase to 0.18, while Return On Capital Employed is projected to decrease to 0.07. As of now, Laboratory's Other Current Assets are increasing as compared to previous years. The Laboratory's current Total Current Assets is estimated to increase to about 5 B, while Intangible Assets are projected to decrease to under 2.1 B.The Laboratory's current Common Stock Shares Outstanding is estimated to increase to about 96 M, while Net Income Applicable To Common Shares is projected to decrease to under 669.3 M.
Laboratory Workforce Comparison
Laboratory of is rated third overall in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 295,543. Laboratory totals roughly 60,900 in number of employees claiming about 21% of equities under Health Care industry.
Laboratory Profit Margins
The company has Net Profit Margin (PM) of 0.06 %, which suggests that even a small decline in it sales will erase profits and may result in a net loss, or a negative profit margin. This is way below average. Likewise, it shows Net Operating Margin (NOM) of 0.1 %, which signifies that for every $100 of sales, it has a net operating income of $0.1.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.42 | 0.2692 |
|
| |||||
Net Profit Margin | 0.0669 | 0.0573 |
|
| |||||
Operating Profit Margin | 0.17 | 0.0835 |
|
| |||||
Pretax Profit Margin | 0.14 | 0.0738 |
|
| |||||
Return On Assets | 0.0386 | 0.0406 |
|
| |||||
Return On Equity | 0.18 | 0.0926 |
|
|
Laboratory Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Laboratory insiders, such as employees or executives, is commonly permitted as long as it does not rely on Laboratory's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Laboratory insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-06-01 | 0.2222 | 2 | 9 | 4,287 | 17,235 |
2025-03-01 | 0.8586 | 85 | 99 | 199,629 | 88,496 |
2024-12-01 | 0.7778 | 7 | 9 | 28,726 | 40,298 |
2024-06-01 | 0.2857 | 4 | 14 | 21,380 | 45,357 |
2024-03-01 | 0.8056 | 87 | 108 | 303,211 | 297,981 |
2023-12-01 | 0.5 | 2 | 4 | 436.00 | 1,839 |
2023-09-01 | 0.3333 | 1 | 3 | 56.00 | 5,073 |
2023-06-01 | 2.0 | 22 | 11 | 158,353 | 15,832 |
2023-03-01 | 0.9111 | 82 | 90 | 225,878 | 89,157 |
2022-12-01 | 0.7273 | 8 | 11 | 38,739 | 30,103 |
2022-09-01 | 0.2778 | 5 | 18 | 32,917 | 104,567 |
2022-03-01 | 0.9186 | 79 | 86 | 156,968 | 58,112 |
2021-12-01 | 0.2941 | 5 | 17 | 17,058 | 26,724 |
2021-09-01 | 0.5 | 2 | 4 | 4,550 | 9,065 |
2021-06-01 | 0.4286 | 3 | 7 | 8,110 | 18,162 |
2021-03-01 | 0.9 | 72 | 80 | 135,493 | 47,163 |
2020-12-01 | 0.4286 | 6 | 14 | 17,229 | 27,598 |
2020-09-01 | 0.5 | 3 | 6 | 2,420 | 5,443 |
2020-06-01 | 0.2 | 1 | 5 | 1,010 | 33,504 |
2020-03-01 | 0.9605 | 73 | 76 | 293,460 | 118,837 |
2019-12-01 | 1.0 | 9 | 9 | 147,524 | 36,645 |
2019-09-01 | 0.2222 | 2 | 9 | 5,066 | 26,216 |
2019-06-01 | 0.5263 | 10 | 19 | 148,322 | 92,882 |
2019-03-01 | 0.8906 | 57 | 64 | 197,097 | 73,462 |
2018-12-01 | 0.5 | 2 | 4 | 6,874 | 8,360 |
2018-09-01 | 0.25 | 1 | 4 | 153.00 | 2,306 |
2018-06-01 | 0.25 | 5 | 20 | 128,553 | 253,615 |
2018-03-01 | 0.8947 | 68 | 76 | 341,205 | 239,230 |
2017-09-01 | 0.381 | 8 | 21 | 213,123 | 439,693 |
2017-06-01 | 0.8 | 4 | 5 | 17,432 | 11,573 |
2017-03-01 | 0.8312 | 64 | 77 | 350,653 | 176,413 |
2016-12-01 | 1.0 | 2 | 2 | 49,901 | 31,601 |
2016-09-01 | 0.2 | 1 | 5 | 992.00 | 11,161 |
2016-06-01 | 0.3 | 3 | 10 | 200,450 | 411,918 |
2016-03-01 | 0.7179 | 56 | 78 | 312,339 | 252,898 |
2015-12-01 | 0.25 | 2 | 8 | 3,146 | 6,006 |
2015-09-01 | 0.375 | 3 | 8 | 119,990 | 229,576 |
2015-06-01 | 0.2632 | 5 | 19 | 57,060 | 113,853 |
2015-03-01 | 0.6667 | 44 | 66 | 144,102 | 159,333 |
2014-12-01 | 0.3333 | 1 | 3 | 624.00 | 1,718 |
2014-09-01 | 0.3 | 3 | 10 | 195,700 | 393,400 |
2014-06-01 | 1.1053 | 21 | 19 | 127,379 | 191,432 |
2014-03-01 | 0.4138 | 12 | 29 | 125,329 | 145,306 |
2013-12-01 | 0.6 | 6 | 10 | 100,024 | 188,800 |
2013-09-01 | 0.5 | 4 | 8 | 100,000 | 132,429 |
2013-06-01 | 0.6296 | 17 | 27 | 320,270 | 584,451 |
2013-03-01 | 0.4706 | 8 | 17 | 105,453 | 41,638 |
2012-09-01 | 0.625 | 5 | 8 | 149,294 | 254,830 |
2012-06-01 | 3.0 | 9 | 3 | 285,700 | 5,687 |
2012-03-01 | 0.5 | 15 | 30 | 260,005 | 274,061 |
2011-12-01 | 0.5 | 1 | 2 | 20,000 | 40,000 |
2011-09-01 | 0.6667 | 2 | 3 | 1,353 | 2,170 |
2011-06-01 | 1.3333 | 12 | 9 | 22,792 | 22,909 |
2011-03-01 | 0.6207 | 18 | 29 | 438,936 | 102,157 |
2010-12-01 | 0.375 | 3 | 8 | 65,366 | 132,494 |
2010-09-01 | 0.75 | 3 | 4 | 14,096 | 4,716 |
2010-06-01 | 1.4286 | 10 | 7 | 31,000 | 36,686 |
2010-03-01 | 0.65 | 13 | 20 | 487,600 | 78,161 |
2009-12-01 | 0.2 | 1 | 5 | 4,116 | 22,080 |
2009-09-01 | 1.0 | 2 | 2 | 50,700 | 854.00 |
2009-06-01 | 2.0 | 8 | 4 | 19,200 | 33,707 |
2009-03-01 | 0.5217 | 12 | 23 | 608,000 | 25,320 |
2008-06-01 | 0.371 | 23 | 62 | 568,776 | 12,548 |
2008-03-01 | 0.0755 | 33 | 437 | 354,093 | 385,564 |
2007-12-01 | 0.7143 | 15 | 21 | 35,260 | 72,386 |
2007-09-01 | 1.5455 | 17 | 11 | 95,452 | 95,856 |
2007-06-01 | 0.3218 | 28 | 87 | 39,074 | 82,599 |
2007-03-01 | 0.3179 | 48 | 151 | 631,190 | 228,173 |
2006-12-01 | 1.3636 | 15 | 11 | 14,288 | 28,000 |
2006-09-01 | 1.0556 | 19 | 18 | 27,060 | 53,993 |
2006-06-01 | 0.5962 | 31 | 52 | 90,974 | 170,945 |
2006-03-01 | 0.1429 | 57 | 399 | 976,027 | 1,306,343 |
2005-12-01 | 1.6667 | 15 | 9 | 13,996 | 29,233 |
2005-09-01 | 2.25 | 18 | 8 | 61,125 | 121,546 |
2005-06-01 | 0.7273 | 32 | 44 | 101,455 | 174,097 |
2005-03-01 | 0.1489 | 35 | 235 | 505,023 | 713,208 |
2004-12-01 | 0.5972 | 43 | 72 | 546,198 | 1,089,771 |
2004-09-01 | 9.0 | 18 | 2 | 3,303 | 286.00 |
2004-06-01 | 0.6735 | 33 | 49 | 143,456 | 206,000 |
2004-03-01 | 0.1051 | 29 | 276 | 691,714 | 812,942 |
2003-12-01 | 0.6154 | 16 | 26 | 64,604 | 70,000 |
2003-09-01 | 0.6 | 12 | 20 | 19,700 | 62,962 |
Laboratory Notable Stakeholders
A Laboratory stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Laboratory often face trade-offs trying to please all of them. Laboratory's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Laboratory's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Paul Kirchgraber | Executive Vice President and Chief Executive Officer - Covance Drug Development | Profile | |
Adam Schechter | Chairman of the Board, President, Chief Executive Officer | Profile | |
Glenn Eisenberg | Chief Financial Officer, Executive Vice President | Profile | |
Lance Berberian | Executive Vice President, Chief Technology Officer, Chief Information Officer | Profile | |
JD MD | President EVP | Profile | |
Peter Wilkinson | Senior Vice President, Chief Accounting Officer | Profile | |
Brian Caveney | Executive Vice President, President, Diagnostics and Chief Medical Officer | Profile | |
Sandra Vaart | Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary | Profile | |
Julia Wang | CFO VP | Profile | |
Kerrii Anderson | Independent Director | Profile | |
JeanLuc Belingard | Independent Director | Profile | |
Peter Neupert | Lead Independent Director | Profile | |
Richelle Parham | Independent Director | Profile | |
Robert Williams | Independent Director | Profile | |
Jeffrey Davis | Independent Director | Profile | |
Garheng Kong | Independent Director | Profile | |
Marcia Eisenberg | Enterprise VP | Profile | |
Sandra JD | Chief VP | Profile | |
Deborah SesokPizzini | SVP Officer | Profile | |
Akinbolade Oyegunwa | Executive Officer | Profile | |
Anita Graham | Executive Officer | Profile | |
Judith Seltz | Chief Human Resource Officer, Executive Vice President | Profile | |
Michelle Abelson | Laboratory Operations | Profile | |
Jonathan DiVincenzo | Executive International | Profile | |
Amy Summy | Executive Vice President Chief Marketing Officer | Profile | |
Mark Schroeder | Executive Vice President and Presidentident of Diagnostics Laboratory Operations and Global Supply Chain | Profile | |
Robert Pringle | Senior Treasurer | Profile | |
Paul MD | Ex Devel | Profile | |
John Treadwell | Vice Initiatives | Profile | |
D Gilliland | Independent Director | Profile | |
Akinbolade MBA | Executive Officer | Profile | |
Kathryn Wengel | Independent Director | Profile | |
Christin ODonnell | Vice Relations | Profile | |
Megan MPH | Executive Officer | Profile | |
Chas Cook | VP Relations | Profile | |
MPH MD | Pres VP | Profile |
About Laboratory Management Performance
The success or failure of an entity such as Laboratory often depends on how effective the management is. Laboratory management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Laboratory management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Laboratory management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.09 | 0.14 | |
Return On Capital Employed | 0.07 | 0.07 | |
Return On Assets | 0.04 | 0.04 | |
Return On Equity | 0.09 | 0.18 |
Laboratory Workforce Analysis
Traditionally, organizations such as Laboratory use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Laboratory within its industry.Laboratory Manpower Efficiency
Return on Laboratory Manpower
Revenue Per Employee | 213.6K | |
Revenue Per Executive | 361.4M | |
Net Income Per Employee | 12.2K | |
Net Income Per Executive | 20.7M | |
Working Capital Per Employee | 24.2K | |
Working Capital Per Executive | 41M |
Complementary Tools for Laboratory Stock analysis
When running Laboratory's price analysis, check to measure Laboratory's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Laboratory is operating at the current time. Most of Laboratory's value examination focuses on studying past and present price action to predict the probability of Laboratory's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Laboratory's price. Additionally, you may evaluate how the addition of Laboratory to your portfolios can decrease your overall portfolio volatility.
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |